Drug shows promise for Long-Term seizure control in rare disease

NCT ID NCT02962414

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of everolimus in people with tuberous sclerosis complex (TSC) who have seizures that are hard to control. Participants are already taking everolimus and benefiting from it in an earlier study. The goal is to see if the drug remains safe and helpful over a longer period. About 206 people are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus
What this could lead to: If successful, this study could confirm that everolimus is safe and effective for long-term seizure control in people with tuberous sclerosis complex.
What could go wrong: This is an open-label roll-over study with no placebo group, so results may be biased. It only includes people already benefiting, so it may not reflect real-world outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberous sclerosis tuberous sclerosis 1 visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBEROUS SCLEROSIS COMPLEX

Contacts and locations

Locations

Atlantic Health Systems

Morristown, New Jersey, 07962, United States
Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cinn Children Hosp Medical Center

Cincinnati, Ohio, 45229-3039, United States
Connecticut Childrens Medical Cntr

Hartford, Connecticut, 06106, United States
David Geffen School of Medicine at UCLA

Los Angeles, California, 90005-1752, United States
Minnesota Epilepsy Group

Saint Paul, Minnesota, 55102, United States
Novartis Investigative Site

Sydney, New South Wales, 2031, Australia
Novartis Investigative Site

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site

Brussels, 1090, Belgium
Novartis Investigative Site

Brussels, 1200, Belgium
Novartis Investigative Site

Ghent, 9000, Belgium
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Vancouver, British Columbia, V6H 3V4, Canada
Novartis Investigative Site

Cali, Valle del Cauca Department, 760032, Colombia
Novartis Investigative Site

Amiens, 80054, France
Novartis Investigative Site

Bron, 69677, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Budapest, 1145, Hungary
Novartis Investigative Site

Bari, BA, 70124, Italy
Novartis Investigative Site

Bologna, BO, 40139, Italy
Novartis Investigative Site

Pavia, PV, 27100, Italy
Novartis Investigative Site

Roma, RM, 00161, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Suita, Osaka, 565-0871, Japan
Novartis Investigative Site

Shizuoka, Shizuoka, 4208688, Japan
Novartis Investigative Site

Okayama, 7008558, Japan
Novartis Investigative Site

Osaka, 5340021, Japan
Novartis Investigative Site

Guadalajara, Jalisco, 44280, Mexico
Novartis Investigative Site

Warsaw, 04-730, Poland
Novartis Investigative Site

Samara, Samara Oblast, 443095, Russia
Novartis Investigative Site

Moscow, 119991, Russia
Novartis Investigative Site

Moscow, 127412, Russia
Novartis Investigative Site

Voronezh, 394024, Russia
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Donostia / San Sebastian, Gipuzkoa, 20014, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site

Tainan, 704302, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Bangkok, 10400, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site

Birmingham, West Midlands, B15 2TH, United Kingdom
Novartis Investigative Site

Buckinghamshire, SL9 0RJ, United Kingdom
Novartis Investigative Site

Cambridge, CB2 0QQ, United Kingdom
Novartis Investigative Site

Liverpool, L12 2AP, United Kingdom
Novartis Investigative Site

London, SW17 0QT, United Kingdom
Novartis Investigative Site

London, WC1N 3JH, United Kingdom
Novartis Investigative Site

Sheffield, S10 2TH, United Kingdom
Novartis Investigative Site

York, YO31 7EX, United Kingdom
Oregon Health Sciences University

Portland, Oregon, 97239, United States
Rady Children s Hospital

San Diego, California, 92123, United States
TGen APNNA

Phoenix, Arizona, 85012, United States
Texas Childrens Hospital

Houston, Texas, 77030, United States
Texas Scottish Rite Hos for Child

Dallas, Texas, 75219, United States
UCSF Benioff Children s Hospital

Oakland, California, 94609, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Colorado School of Medicine

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.